These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38134061)

  • 1. Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
    Huo X; Wang Y; Ma S; Zhu S; Wang K; Ji Q; Chen F; Wang L; Wu Z; Li W
    Medicine (Baltimore); 2023 Dec; 102(51):e36581. PubMed ID: 38134061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
    Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [
    Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
    Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
    Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas.
    Wu S; Zhang X; Rui W; Sheng Y; Yu Y; Zhang Y; Yao Z; Qiu T; Ren Y
    Eur Radiol; 2022 May; 32(5):3187-3198. PubMed ID: 35133485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
    Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
    Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
    Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
    Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive prediction of IDH mutation status in gliomas using preoperative multiparametric MRI radiomics nomogram: A mutlicenter study.
    Lu J; Xu W; Chen X; Wang T; Li H
    Magn Reson Imaging; 2023 Dec; 104():72-79. PubMed ID: 37778708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
    Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
    Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.
    Wang H; Zhang S; Xing X; Yue Q; Feng W; Chen S; Zhang J; Xie D; Chen N; Liu Y
    Cancer Med; 2023 Feb; 12(3):2524-2537. PubMed ID: 36176070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
    Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
    Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.
    Li Y; Liu X; Qian Z; Sun Z; Xu K; Wang K; Fan X; Zhang Z; Li S; Wang Y; Jiang T
    Eur Radiol; 2018 Jul; 28(7):2960-2968. PubMed ID: 29404769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.